Transition Bio is a technology company.
Transition Bio has raised $50.0M across 1 funding round.
Transition Bio has raised $50.0M in total across 1 funding round.
Transition Bio is a biotechnology company developing a proprietary drug discovery platform focused on biomolecular condensates, particularly targeting intrinsically disordered proteins (IDPs) that drive diseases like cancer and neuromuscular disorders[1][2][3][4]. The platform combines droplet microfluidics, high-throughput molecular screening, cellular imaging, and machine learning/AI to identify and optimize small-molecule hits, delivering unique molecular-level insights into condensate systems for faster, more effective drug development[1][2][5]. It serves pharmaceutical partners and addresses "unsolvable" targets by revealing mechanisms of action and prioritizing indications, with a lead preclinical program in YTHDC1 inhibitors for MYC-driven cancers showing robust efficacy alone and in combinations[2][4]. The company raised $50 million in Series A financing and recently advanced leadership with CEO Gregory Miller, positioning it for accelerated growth in condensate-targeted therapies[2].
Transition Bio emerged from groundbreaking academic research at Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, uniting expertise in droplet microfluidics, cellular imaging, physics, chemistry, biology, and machine learning to tackle biomolecular condensates—a key but undruggable area in disease biology[2][3]. Co-founded by Professor Tuomas Knowles (CTO, University of Cambridge, expert in protein biophysics with 300+ papers and five prior spinouts) and Dr. Samuel Cohen (Executive Director, serial entrepreneur with PhD in Biophysical Chemistry from Cambridge and prior CEO of Wren Therapeutics), the company formalized this integration to commercialize "condensomics"—a four-component platform for studying condensate properties[3][4]. Early milestones include the 2022-ish Series A close and 2025 AACR-NCI-EORTC presentation of lead program data, alongside key hires like CEO Gregory Miller, COO, and board additions such as Kathy Yi (ex-CFO at Cerevel and Sangamo)[2][3].
Transition Bio rides the biomolecular condensate wave, a transformative trend recognizing condensates—dynamic protein-RNA hubs—as drivers of diseases like cancer, neurodegeneration, and myotonic dystrophy, previously deemed undruggable due to their disordered nature[1][2][4]. Timing is ideal amid surging AI-biotech convergence (post-AlphaFold era) and microfluidics advances, amplified by market forces like $50M+ funding for platform plays and demand for novel modalities beyond antibodies[2]. By influencing the ecosystem through open science insights (300+ founder papers) and partnerships, it pioneers "condensate drugging," potentially unlocking billions in untapped markets while validating physics-ML hybrids for precision medicine[3].
Transition Bio is primed to disrupt drug discovery by scaling its condensate platform into clinical assets, with the YTHDC1 program likely advancing to IND filing soon after 2025 data readouts, alongside pipeline expansion in oncology and rare diseases[2][4]. Trends like AI-driven hit-to-lead acceleration and multi-omics integration will fuel momentum, potentially drawing Big Pharma deals or follow-on funding. Its influence could evolve from pioneer to category leader, redefining "undruggable" targets and cementing condensates as a core biotech pillar—echoing its mission to solve the unsolvable at the molecular level[1][2].
Transition Bio has raised $50.0M in total across 1 funding round.
Transition Bio's investors include Abingworth, Northpond Ventures, Novo Ventures.
Transition Bio has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $50.0M Series A | Abingworth, Northpond Ventures, Novo Ventures |